Supporting moral, ethical and commonsense psilocybin laws.

SUBSCRIBE: https://www.youtube.com/roguerocket?sub_confirmation=1 Want More News?: http://RogueRocket.com/Support Snag some http://BeautifulBastard.com pomade, beard oil, and candles to look good, feel good, and of course, it helps support the show! Support this content w/ a Paid subscription @ http://DeFrancoElite.com Watch The Previous RR Video: https://youtu.be/PnfgIn6xM2Q Watch The PDS: https://youtu.be/R-Vu6AmeKr4 ———————————— Follow Us on Social ———————————— TWITTER: https://twitter.com/TheRogueRocket FACEBOOK: https://www.facebook.com/TheRogueRocket/ INSTAGRAM: https://www.instagram.com/theroguerocket/ ———————————— Sources/Important Links: https://journals.sagepub.com/doi/pdf/10.1177/0269881116675513 http://www.maps.org/research-archive/w3pb/2006/2006_Moreno_22868_1.pdf https://link.springer.com/article/10.1007/s13311-017-0542-y https://heffter.org/ https://compasspathways.com/ https://www.wired.com/story/inside-the-push-to-legalize-magic-mushrooms-for-depression-and-ptsd/ https://www.sciencedirect.com/science/article/pii/S0028390818302296 https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html https://www.youtube.com/watch?time_continue=2&v=6ClPE7lLqsc https://psi-2020.org/the-measure/ https://www.gjsentinel.com/opinion/editorials/mushrooms-shouldn-t-be-decriminalized/article_20e20362-71e0-11e9-9e7c-20677ce06c14.html https://www.forbes.com/sites/tomangell/2019/06/08/aoc-pushes-to-make-it-easier-to-study-shrooms-and-other-psychedelic-drugs/#6e4cb3291002 https://www.marijuanamoment.net/pete-buttigieg-proposes-decriminalizing-all-drug-possession-in-mental-health-reform-plan/ https://www.desmoinesregister.com/story/news/politics/2019/02/12/iowa-republican-jeff-shipley-decriminalize-use-psychedelic-drugs-mushrooms-legislature-statehouse/2801439002/ ———————————— Wanna send us stuff? ATTN: Rogue Rocket 4804 Laurel Canyon Blvd. Box - 760 Valley Village, CA 91607 ________________________ Edited by: Jason Mayer Produced by: Amanda Morones, Alex Myers Coordinating Producer: Keith Battista Art Director: Brian Borst Writing/Research: Alex Myers, Brian Espinoza, Philip DeFranco Music By: Jason Mayer ———————————— #DeFranco #Psilocybin #MagicMushrooms ————————————

Denver leaders worry that would make the city more of a destination for drug use More local videos here: https://bit.ly/2Pa0d1l Subscribe to NEXT: http://bit.ly/2eP1GwI Stay connected: 9NEWS Website: http://www.9news.com/ Facebook: https://www.facebook.com/ilike9news Twitter: https://twitter.com/9NEWS Instagram: https://www.instagram.com/9newsdenver/ Google+: https://plus.google.com/+9news/posts Snapchat: Denver9NEWS Pinterest: https://www.pinterest.com/9news/ 9NEWS (KUSA) is located in Denver, Colorado.

Kathleen Conneally successfully quit smoking, after a decades-long habit, with the help of psilocybin. Conneally was a participant in a study at Johns Hopkins University looking at whether nicotine addiction could be treated by psilocybin, the active compound in magic mushrooms. In this short video, staff writer Olga Khazan speaks with Conneally about her experience and uncovers the science of how psychedelics work in the brain to make this possible. Subscribe to The Atlantic on YouTube: http://bit.ly/subAtlanticYT

A clinical psychologist from Imperial College describes how Magic Mushrooms (Psilocybin), when used in a therapeutic setting, have been found to be a very effective treatment for depression. In this talk she draws on her experiences as working as a therapist on the groundbreaking Psilocybin for Depression study, and introduces us to some of the patients and their stories of transformation. Dr Rosalind Watts completed her clinical psychology training at University College London. After six years of practicing psychotherapy in the NHS, she joined a clinical trial at Imperial College, investigating psilocybin (magic mushrooms) as a treatment for depression. Her research explores patients' positive views of this intriguing therapy. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx

More than 180 species of "magic" mushrooms produce the psychoactive compound psilocybin. When you ingest psilocybin, your gut converts it into another chemical called psilocin, which triggers changes in the brain. It increases activity in the visual cortex, leading to changes in perception; it decreases network activity in the "Default Mode Network," driving the experience of ego loss; and it increases connectivity among different regions of the brain. Researchers believe it's the combination of these effects that makes psilocybin an effective tool for combating depression and addiction, for which research shows support. MORE BRAIN SCIENCE CONTENT: What Ketamine Actually Does To Your Brain https://www.youtube.com/watch?v=d_ey_a_yN6Q&t=20s How Giving Birth Changes Your Brain https://www.youtube.com/watch?v=KJqDRCyEX4o What Happens To Your Body When You Drink Too Much Coffee https://www.youtube.com/watch?v=1_6_6TAuoGc&t=5s ------------------------------------------------------ #Psychology #Mushrooms #ScienceInsider Science Insider tells you all you need to know about science: space, medicine, biotech, physiology, and more. Visit us at: https://www.businessinsider.com Science Insider on Facebook: https://www.facebook.com/BusinessInsiderScience/ Science Insider on Instagram: https://www.instagram.com/science_insider/ Business Insider on Twitter: https://twitter.com/businessinsider Tech Insider on Twitter: https://twitter.com/techinsider Business Insider/Tech Insider on Amazon Prime: http://read.bi/PrimeVideo How Magic Mushrooms Affect Your Brain

MAPS is a non-profit organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We are currently seeking funding in support of MAPS’ mission to make psychedelic therapy a legal treatment around the world. * Give the gift of healing: https://maps.org/give * In MAPS’ completed Phase 2 trials with 107 participants, 56% no longer qualified for PTSD after treatment with MDMA-assisted psychotherapy, measured two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. Based on these results, the FDA granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in August 2017. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. * Learn more: https://maps.org * For a limited time, all gifts to MAPS will be doubled up to $50,000 by Justin Rosenstein! By making a tax-deductible donation to MAPS, you can help heal posttraumatic stress disorder (PTSD), anxiety, addiction, and other conditions. With your help, we can work towards healing more people than ever before. * Make a donation: https://maps.org/give * Thank you for your support! --- Video Credits: — Video Co-Producer: Andrew J. O'Keefe II (https://andrewjokeefe.com) — Music: Erothyme - "Where Does Your Love Go?" (https://erothyme.com) — Music: Jon Hopkins - "Feel First Life" (https://jonhopkins.co.uk)

http://psychedelicscience.org Help us caption and translate this video on Amara.org:‪ ‬http://www.amara.org/en/videos/K8X00SfbZCAQ/info/ Brain Imaging Studies with Psilocybin and MDMA Robin Carhart-Harris, PhD Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization. Additionally, he will report the effects of both drugs on brain and subjective responses to personal autobiographical memory cues. A general theory will be presented on how psychedelics alter brain activity to alter consciousness and the implications of these brain imaging results for therapeutic applications of psychedelics will be discussed. A general theory will be presented on how psychedelics alter brain activity to alter consciousness and the implications of these brain imaging results for therapeutic applications of psychedelics will be discussed. Robin Carhart-Harris completed his doctorate in psychopharmacology at the University of Bristol in 2009 after which he moved to Imperial College London to continue his fMRI research with the classic psychedelic drug psilocybin. In the last few years, Carhart-Harris & Professor David Nutt have built up a programme of research with psychedelics that includes fMRI and MEG imaging with psilocybin, fMRI with MDMA and soon an MRC-sponsored clinical trial to assess the efficacy of psilocybin as a treatment for major depression. Carhart-Harris has a review article published in Brain on the neurobiology of Freudian constructs and his work with psilocybin is now published in PNAS, the British Journal of Psychiatry, and Schizophrenia Bulletin. Carhart-Harris has been supported by the Beckley Foundation, the Neuropsychoanalysis Foundation, the Heffter Foundation, and MAPS. More videos available at http://psychedelicscience.org At Psychedelic Science 2013, over 100 of the world's leading researchers and more than 1,900 international attendees gathered to share recent findings on the benefits and risks of LSD, psilocybin, MDMA, ayahuasca, ibogaine, 2C-B, ketamine, DMT, marijuana, and more, over three days of conference presentations, and two days of pre- and post-conference workshops.

A conversation with psychologist and neuroscientist Robin Carhart-Harris on his work to explore the untapped potential of psychedelic drugs to provide effective treatment where today's medicine falls short Interviewed by: · Alyson Shontell Lombardi, Editor-in-Chief, Business Insider US, Business Insider, USA. With: · Robin Carhart-Harris, Head, Centre for Psychedelic Research, University of Oxford, United Kingdom. http://www.weforum.org/